Latest News
May 12, 2021
First quarter of 2021:
Bayer: successful start to 2021
May 10, 2021
Not intended for U.S. and UK Media
Bayer’s finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
April 27, 2021
CEO Werner Baumann at the Annual Stockholders’ Meeting of Bayer AG:
“We’re optimistic for the future”